id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-297661-62s3bdeu	Mahajan, Ruchi	Eculizumab treatment for renal failure in a pediatric patient with COVID-19	2020-09-26		.txt	text/plain	1898	126	46	The incidence and etiology of acute kidney injury (AKI) amongst pediatric patients remains largely unknown. To our knowledge, we present the first pediatric case of COVID-19 and severe AKI due to TMA, treated with eculizumab. She was found to have elevated C5b9 level (1669 ng/L; normal < 244), and given high suspicion for complement-mediated TMA, she was treated with eculizumab 900 mg IV weekly × 3 doses. A case series from 5 patients in New York demonstrated a pattern of tissue damage consistent with complement-mediated microvascular injury in the lungs and skin [5] . Thus, we present this case as the first use of eculizumab for complement inhibition in pediatric complement-mediated AKI, associated with COVID-19 infection. Complement-mediated TMA should be considered as an etiology for AKI in COVID-19 patients. We present a case of complement cascade inhibition using eculizumab as a strategy for treating severe AKI in a pediatric patient.	./cache/cord-297661-62s3bdeu.txt	./txt/cord-297661-62s3bdeu.txt